8-K current report · filed Oct 23, 2026

Akebia Therapeutics, Inc. (AKBA) 8-K Current Report: October 23, 2026

Item 3.01AKBA overview

Short answer

Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

Akebia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.01 · Notice of Delisting

  • Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days
  • No immediate delisting: initial 180-day cure period runs through April 19, 2027
  • Compliance requires at least $1.00 closing bid for 10 consecutive business days
  • Potential second 180-day period, with reverse stock split a possible remedy
  • Failure to cure could trigger delisting proceedings and Nasdaq Hearings Panel appeal риска

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Akebia Therapeutics, Inc. 8-K filings

Get the next AKBA 8-K as it lands

Follow AKBA for push alerts, or ask the research agent what this filing means.